Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
There was no observation related to data integrity reported
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Subscribe To Our Newsletter & Stay Updated
